Each tablet contains Sitagliptin 50 mg/100 mg + Metformin Hydrochloride SR 500 mg/1000 mg.

Sitapride M Tablets combine Sitagliptin, a selective DPP-4 inhibitor, with Sustained-Release Metformin, a biguanide antihyperglycaemic agent, to provide effective glycaemic control in adults with type 2 diabetes mellitus. Sitagliptin enhances glucose-dependent insulin secretion by increasing incretin hormone activity, while Metformin reduces hepatic glucose production, decreases intestinal glucose absorption, and improves peripheral insulin sensitivity. The sustained-release formulation of Metformin offers improved gastrointestinal tolerability and convenient once-daily dosing.

Sitapride M Tablets are indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus.

Sitagliptin is a DPP-4 inhibitor that slows the degradation of incretin hormones, thereby increasing glucose-dependent insulin secretion and reducing glucagon secretion. Metformin is an antihyperglycaemic agent that lowers both fasting and postprandial plasma glucose by decreasing hepatic glucose production, reducing intestinal glucose absorption, and enhancing peripheral glucose uptake and insulin sensitivity. The combination provides complementary mechanisms for improved glycaemic control.

The recommended dosage is one tablet orally once daily with food, or as directed by the physician.

Sitapride M Tablets are contraindicated in patients with a history of serious hypersensitivity reactions to sitagliptin, metformin, or any component of the formulation, and in patients with metabolic acidosis, including diabetic ketoacidosis.